These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 25733005)

  • 21. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
    Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
    Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
    Zhou X; Vaishampayan U; Mahalingam D; Harvey RD; Chung KY; Sedarati F; Dong C; Faller DV; Venkatakrishnan K; Gupta N
    Invest New Drugs; 2022 Oct; 40(5):1042-1050. PubMed ID: 35932388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
    Tarlock K; Liu X; Minard CG; Isikwei EA; Reid JM; Horton TM; Fox E; Weigel BJ; Cooper T
    Pediatr Blood Cancer; 2023 Dec; 70(12):e30672. PubMed ID: 37710306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924).
    Sumi H; Inazuka M; Morimoto M; Hibino R; Hashimoto K; Ishikawa T; Kuida K; Smith PG; Yoshida S; Yabuki M
    Biochem Biophys Res Commun; 2016 Nov; 480(3):380-386. PubMed ID: 27771247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27
    Chen Y; Du M; Yusuying S; Liu W; Tan Y; Xie P
    Exp Cell Res; 2020 Jul; 392(2):112038. PubMed ID: 32360865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
    Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
    Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
    Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.
    Pai CS; Khuat LT; Chen M; Murphy WJ; Abedi M
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):30-37. PubMed ID: 27815049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.
    Yan ZH; Burkhardt A; Loke HK; Chen J; Xu Q; Brauer P; Ma J; Lin Y; Garcia K; Dick LR; Bembenek ME
    Anal Biochem; 2013 Aug; 439(2):109-15. PubMed ID: 23624319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
    Martinelli G; Oehler VG; Papayannidis C; Courtney R; Shaik MN; Zhang X; O'Connell A; McLachlan KR; Zheng X; Radich J; Baccarani M; Kantarjian HM; Levin WJ; Cortes JE; Jamieson C
    Lancet Haematol; 2015 Aug; 2(8):e339-46. PubMed ID: 26688487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
    Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
    Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
    Zeidan AM; DeAngelo DJ; Palmer J; Seet CS; Tallman MS; Wei X; Raymon H; Sriraman P; Kopytek S; Bewersdorf JP; Burgess MR; Hege K; Stock W
    Ann Hematol; 2022 Mar; 101(3):557-569. PubMed ID: 34981142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.
    Paiva C; Godbersen JC; Berger A; Brown JR; Danilov AV
    Cell Death Dis; 2015 Jul; 6(7):e1807. PubMed ID: 26158513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.
    Leclerc GM; Zheng S; Leclerc GJ; DeSalvo J; Swords RT; Barredo JC
    Leuk Res; 2016 Nov; 50():1-10. PubMed ID: 27626202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
    Cortes J; Faderl S; Estey E; Kurzrock R; Thomas D; Beran M; Garcia-Manero G; Ferrajoli A; Giles F; Koller C; O'Brien S; Wright J; Bai SA; Kantarjian H
    J Clin Oncol; 2005 Apr; 23(12):2805-12. PubMed ID: 15728224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
    Buckley SA; Mawad R; Gooley TA; Becker PS; Sandhu V; Hendrie P; Scott BL; Wood BL; Walter RB; Smith K; Dean C; Estey EH; Pagel JM
    Br J Haematol; 2015 Aug; 170(3):349-55. PubMed ID: 25854284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Torka P; Thiruvengadam SK; Chen L; Wang X; Chen C; Vuong D; Qin H; Muir A; Orand K; Borja I; Lynne Smith D; Herrera AF; Spurgeon SEF; Park B; Lewis LD; Hernandez-Ilizaliturri F; Xia Z; Danilov AV
    Blood Cancer J; 2023 Jan; 13(1):9. PubMed ID: 36631449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.